Distinct and evolutionary conserved structural features of the human nuclear exosome complex
- Max Planck Institute of Biochemistry, Germany
Abstract
The nuclear RNA exosome complex mediates the processing of structured RNAs and the decay of aberrant non-coding RNAs, an important function particularly in human cells. Most mechanistic studies to date have focused on the yeast system. Here, we reconstituted and studied the properties of a recombinant 14-subunit human nuclear exosome complex. In biochemical assays, the human exosome embeds a longer RNA channel than its yeast counterpart. The 3.8 Å resolution cryo-EM structure of the core complex bound to a single-stranded RNA reveals that the RNA channel path is formed by two distinct features of the hDIS3 exoribonuclease: an open conformation and a domain organization more similar to bacterial RNase II than to yeast Rrp44. The cryo-EM structure of the holo-complex shows how obligate nuclear cofactors position the hMTR4 helicase at the entrance of the core complex, suggesting a striking structural conservation from lower to higher eukaryotes.
Data availability
The cryo-EM density maps are deposited in the Electron Microscopy Data Bank under accession numbers EMD-0127 and EMD-0128. The atomic model is deposited in the Protein Data Bank (PDB) under accession number 6H25.
-
Human nuclear RNA exosome EXO-14 complex (cryo-EM density map)Publicly available at the Electron Microscopy Data Bank (accession no: EMD-0127).
-
Cryo-EM density mapPublicly available at the Electron Microscopy Data Bank (accession no: EMD-0128).
-
Human nuclear RNA exosome EXO-10-MPP6 complex (atomic model)Publicly available at the RCSB Protein Data Bank (accession no: 6H25).
Article and author information
Author details
Funding
European Molecular Biology Organization (ALTF 1008-2015)
- Piotr Gerlach
European Commission (ERC-2016-ADG 740329 EXORICO)
- Elena Conti
Deutsche Forschungsgemeinschaft (SFB646)
- Elena Conti
Louis-Jeantet Foundation
- Elena Conti
Max-Planck-Gesellschaft
- Elena Conti
Deutsche Forschungsgemeinschaft (SFB1035)
- Elena Conti
Deutsche Forschungsgemeinschaft (GRK1721)
- Elena Conti
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Sjors HW Scheres, MRC Laboratory of Molecular Biology, United Kingdom
Publication history
- Received: May 26, 2018
- Accepted: July 17, 2018
- Accepted Manuscript published: July 26, 2018 (version 1)
- Version of Record published: August 2, 2018 (version 2)
Copyright
© 2018, Gerlach et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,935
- Page views
-
- 556
- Downloads
-
- 27
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Distinct and evolutionary conserved structural features of the human nuclear exosome complex
eLife 7:e38686.
https://doi.org/10.7554/eLife.38686
Further reading
-
- Biochemistry and Chemical Biology
Tyrosine kinases and SH2 (phosphotyrosine recognition) domains have binding specificities that depend on the amino acid sequence surrounding the target (phospho)tyrosine residue. Although the preferred recognition motifs of many kinases and SH2 domains are known, we lack a quantitative description of sequence specificity that could guide predictions about signaling pathways or be used to design sequences for biomedical applications. Here, we present a platform that combines genetically encoded peptide libraries and deep sequencing to profile sequence recognition by tyrosine kinases and SH2 domains. We screened several tyrosine kinases against a million-peptide random library and used the resulting profiles to design high-activity sequences. We also screened several kinases against a library containing thousands of human proteome-derived peptides and their naturally-occurring variants. These screens recapitulated independently measured phosphorylation rates and revealed hundreds of phosphosite-proximal mutations that impact phosphosite recognition by tyrosine kinases. We extended this platform to the analysis of SH2 domains and showed that screens could predict relative binding affinities. Finally, we expanded our method to assess the impact of non-canonical and post-translationally modified amino acids on sequence recognition. This specificity profiling platform will shed new light on phosphotyrosine signaling and could readily be adapted to other protein modification/recognition domains.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
SARS-CoV-2 emergent variants are characterized by increased viral fitness and each shows multiple mutations predominantly localized to the spike (S) protein. Here, amide hydrogen/deuterium exchange mass spectrometry has been applied to track changes in S dynamics from multiple SARS-CoV-2 variants. Our results highlight large differences across variants at two loci with impacts on S dynamics and stability. A significant enhancement in stabilization first occurred with the emergence of D614G S followed by smaller, progressive stabilization in subsequent variants. Stabilization preceded altered dynamics in the N-terminal domain, wherein Omicron BA.1 S showed the largest magnitude increases relative to other preceding variants. Changes in stabilization and dynamics resulting from S mutations detail the evolutionary trajectory of S in emerging variants. These carry major implications for SARS-CoV-2 viral fitness and offer new insights into variant-specific therapeutic development.
